UA111972C2 - Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій - Google Patents

Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій

Info

Publication number
UA111972C2
UA111972C2 UAA201400469A UAA201400469A UA111972C2 UA 111972 C2 UA111972 C2 UA 111972C2 UA A201400469 A UAA201400469 A UA A201400469A UA A201400469 A UAA201400469 A UA A201400469A UA 111972 C2 UA111972 C2 UA 111972C2
Authority
UA
Ukraine
Prior art keywords
rifaximin
treatment
processes
preparation
pharmaceutical compositions
Prior art date
Application number
UAA201400469A
Other languages
English (en)
Inventor
Джузеппе Клаудіо Віскомі
Паола Маффеі
Вітторіа Лауро
Фіорелла Каланні
Беатріче Віталі
Федеріка Кручані
Original Assignee
Альфа Вассерманн С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альфа Вассерманн С.П.А. filed Critical Альфа Вассерманн С.П.А.
Publication of UA111972C2 publication Critical patent/UA111972C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Винахід стосується вагінальної таблетки, яка містить гранули рифаксиміну та охарактеризована вивільненням рифаксиміну в піхві контрольованим шляхом, ефективна при лікуванні вагінальних інфекцій, зокрема бактеріального вагініту; та способу виготовлення вагінальної таблетки рифаксиміну та її застосування для лікування вагінальних інфекцій.
UAA201400469A 2011-07-29 2012-07-26 Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій UA111972C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000461A ITBO20110461A1 (it) 2011-07-29 2011-07-29 Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
PCT/IB2012/001438 WO2013017928A1 (en) 2011-07-29 2012-07-26 Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections

Publications (1)

Publication Number Publication Date
UA111972C2 true UA111972C2 (uk) 2016-07-11

Family

ID=44584299

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201400469A UA111972C2 (uk) 2011-07-29 2012-07-26 Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій

Country Status (20)

Country Link
US (1) US10258610B2 (uk)
EP (1) EP2736488B1 (uk)
JP (1) JP5956575B2 (uk)
CN (1) CN103732212B (uk)
AU (1) AU2012291767B2 (uk)
CA (1) CA2841415C (uk)
DK (1) DK2736488T3 (uk)
EA (1) EA025047B1 (uk)
ES (1) ES2549560T3 (uk)
HR (1) HRP20151095T1 (uk)
HU (1) HUE026465T2 (uk)
IT (1) ITBO20110461A1 (uk)
MX (1) MX2014001139A (uk)
PL (1) PL2736488T3 (uk)
PT (1) PT2736488E (uk)
RS (1) RS54329B1 (uk)
SI (1) SI2736488T1 (uk)
TN (1) TN2014000009A1 (uk)
UA (1) UA111972C2 (uk)
WO (1) WO2013017928A1 (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US10543088B2 (en) * 2012-09-14 2020-01-28 Boston Scientific Scimed, Inc. Mitral valve inversion prostheses
US9610156B2 (en) * 2012-09-14 2017-04-04 Millipede, Inc. Mitral valve inversion prostheses
KR20150129691A (ko) * 2013-03-15 2015-11-20 알파 와셔만 에스.피.아. 질 감염증의 치료에 사용하기 위한 리팍시민
CA2941008C (en) 2014-03-06 2022-07-26 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
DK3546464T3 (da) 2014-05-12 2020-07-27 Alfasigma Spa Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
WO2018069938A1 (en) * 2016-10-14 2018-04-19 Cipla Limited Pharmaceutical compositions comprising rifaximin
CN106860451A (zh) * 2017-02-28 2017-06-20 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的新应用
CN106902116B (zh) * 2017-02-28 2021-03-23 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮双靶标分子的应用
CN113660928B (zh) * 2019-04-05 2024-04-05 盖迪亚生物技术公司 阴道片剂制剂
WO2020254179A1 (en) * 2019-06-21 2020-12-24 Alfasigma S.P.A. Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US5166959A (en) 1991-12-19 1992-11-24 Hewlett-Packard Company Picosecond event timer
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
KR100467532B1 (ko) 1996-10-16 2005-01-24 피에스 팔마큐티칼스 인코퍼레이션 프로안토시아니딘 중합체로 된 항-설사 장용피 조제물
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20070082035A1 (en) * 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
KR101486590B1 (ko) 2006-01-05 2015-01-26 벨로시스 파마슈티컬스 에이/에스 붕해성의 충전형 정제
JP4887928B2 (ja) 2006-06-21 2012-02-29 株式会社デンソー 車両用通信システムの受信装置
AT503862B1 (de) * 2006-07-05 2010-11-15 Arc Austrian Res Centers Gmbh Pathogen-identifizierung anhand eines 16s oder 18s-rrna mikroarray
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2008035109A1 (en) 2006-09-22 2008-03-27 Cipla Limited Rifaximin
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP2420226B1 (en) 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EP2583669A1 (en) * 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
US8772242B2 (en) 2009-10-26 2014-07-08 Thomas Julius Borody Therapy for enteric infections
JP2013511570A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
BR112012012315A2 (pt) 2009-11-23 2018-10-16 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou anus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de silicone e dispensador para composição farmacêutica
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9211258B2 (en) 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension
KR20130086338A (ko) 2010-06-03 2013-08-01 샐릭스 파마슈티컬스 리미티드 리팍시민의 신규한 형태들 및 이들의 용도
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
SI2593463T1 (sl) 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
JP2013537182A (ja) 2010-09-13 2013-09-30 シプラ・リミテッド 医薬組成物
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.

Also Published As

Publication number Publication date
US20130028971A1 (en) 2013-01-31
RS54329B1 (en) 2016-02-29
EA201490264A1 (ru) 2014-08-29
AU2012291767B2 (en) 2016-10-06
EA025047B1 (ru) 2016-11-30
CN103732212B (zh) 2016-06-01
HUE026465T2 (en) 2016-05-30
TN2014000009A1 (en) 2015-07-01
WO2013017928A1 (en) 2013-02-07
PT2736488E (pt) 2015-11-20
SI2736488T1 (sl) 2015-12-31
DK2736488T3 (en) 2015-11-02
JP2014521632A (ja) 2014-08-28
CA2841415A1 (en) 2013-02-07
PL2736488T3 (pl) 2015-12-31
NZ620418A (en) 2015-03-27
ES2549560T3 (es) 2015-10-29
CN103732212A (zh) 2014-04-16
AU2012291767A1 (en) 2014-01-30
ITBO20110461A1 (it) 2013-01-30
CA2841415C (en) 2016-03-22
US10258610B2 (en) 2019-04-16
MX2014001139A (es) 2014-02-27
JP5956575B2 (ja) 2016-07-27
EP2736488A1 (en) 2014-06-04
HRP20151095T1 (hr) 2015-12-04
EP2736488B1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
UA111972C2 (uk) Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
MX370853B (es) Formulaciones que contienen dapagliflozina amorfa.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP3081222A4 (en) Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
IN2012DN02805A (uk)
MY173422A (en) Purine derivatives for the treatment of viral infections
GB201118656D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP2725904A4 (en) HIGH-DOSE MUCOADHESIVE AQUEOUS METRONIZOUS MELTRONIDAZE GEL FORMULATIONS AND USE THEREOF FOR TREATING BACTERIAL VAGINOSIS
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
EA201490862A1 (ru) Осмотически активная система вагинальной доставки
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
UA117672C2 (uk) Антибактеріальні сполуки
WO2013109202A3 (en) Pharmaceutical compounds comprising cefetamet
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria